Highest-materiality recent filing
Streamex and Orca launch 24/7 decentralized secondary liquidity for tokenized securities; GLDY first
GLDY, a gold-backed tokenized security, is the inaugural asset traded on the new Orca pool.
Streamex appoints former Microsoft/PayPal product leader Kori Handy as VP of Product and Design
Kori Handy appointed VP of Product and Design, effective May 26, 2026.
Streamex appoints director, revises CEO/Chairman/CIO employment pacts with milestone bonuses
Mitchell Young Williams appointed to board as non-independent director; effective April 28, 2026.
StreamEx holds webcast on FY2025 results; no specific figures in 8-K
StreamEx hosted a webcast on April 8, 2026 to discuss financial results for the year ended Dec 31, 2025.
StreamEx refutes false S&P IQ report of 89.8M-share lock-up expiry; co-founders sign 1-yr lock-up
Company refutes S&P Capital IQ/MarketScreener post claiming 89,833,535 shares subject to lock-up expiring March 24, 2026; calls it materially inaccurate.
Streamex Corp. Appoints Christine Plummer as CFO, Replaces Ferdinand Groenewald
CFO Ferdinand Groenewald resigned effective March 15, 2026, with severance of $112,500 (6 months base salary) and accelerated vesting of RSUs.
Streamex appoints former Cantor Fitzgerald CEO Shawn Matthews to Board of Directors
Shawn Matthews appointed as independent director effective March 3, 2026; term until next annual meeting.
Streamex appoints Morgan Lekstrom Executive Chairman; repays $38.9M Yorkville debentures
Morgan Lekstrom named Executive Chairman, effective Feb 9, 2026; joins executive leadership team.
Streamex Appoints Anthony Marciano, NYU Stern Professor, to Board as Independent Director
Marciano, Clinical Professor of Finance at NYU Stern, appointed independent director effective Feb 3, 2026.
Streamex terminates $1B SEPA, prepays $50M convertible debentures with 10% premium
Terminated Standby Equity Purchase Agreement with Yorkville; no shares ever sold under the $1B facility.
Streamex closes public offering of 13.4M shares for $40.25M gross proceeds
Offered 11,666,667 shares at $3.00/share for ~$35M; overallotment fully exercised adding 1.75M shares.
Streamex corrects board classification vote, invalidates prior structure
Proposal 6 to classify board received 15.4M votes for but failed to achieve majority of outstanding voting power as required.
Streamex shareholders approve 22.5M share increase to incentive plan at 2025 annual meeting
Shareholders approved increase in authorized shares under 2023 Long-Term Incentive Plan by 22,494,324 to 37,230,130.
StreamEx Corp. issues $25M second tranche convertible debenture to Yorkville
Issued $25M principal convertible debenture to YA II PN (Yorkville) with net proceeds of ~$24M.
Streamex acquires 9.9% stake in Empress Royalty for $12.2M at $5.00 STEX premium
Acquired 12.7M Empress shares from Terra Capital in exchange for 2.44M STEX restricted shares.
Three directors resign; Streamex appoints Kevin Gopaul, adopts classified board
Three directors (Steven Abelman, Christopher Baer, Anthony Amato) resigned effective 11/18/25; no disagreement cited.
Streamex closes $25M convertible debenture; proceeds to purchase physical gold bullion
Issued $25M principal convertible debenture to YA II PN, Ltd.; net proceeds ~$24M (96% of principal).
Stockholders approve issuance of 109M shares to acquire Streamex; deal closed
Special meeting reconvened Nov 4, 2025; Acquisition Proposal approved by stockholders.
Streamex receives Nasdaq approval for continued listing; special meeting Nov 4 for acquisition vote
Nasdaq formally approved continued listing on Nasdaq Capital Market under ticker STEX.
Entered Amendment No. 2 to Secured Convertible Debenture Purchase Agreement with YA II PN, Ltd. (Yorkville) on October 28, 2025.
BioSig Technologies changes name to Streamex Corp.; ticker to STEX
Name change to Streamex Corp. effective 12:01 am ET on September 12, 2025.
BioSig/Streamex partners with Monetary Metals to tokenize gold with up to 4% annual yield target
Exclusive three-year partnership to tokenize yield-bearing gold products from Monetary Metals' lease and bond programs.
Shareholders approved increasing authorized common shares from 200M to 500M (Ninth Certificate of Amendment filed).
Issued 3,852,149 shares of common stock at $3.90/share; gross proceeds ~$15.0M.
BioSig amends debenture agreement with Yorkville: up to $100M in convertible notes
First secured convertible debenture of $25M, second of $25M, additional up to $50M at mutual agreement.
BioSig amends 8-K to provide Streamex business overview, risk factors, and pro forma financials
Streamex generated ~$200,000 revenue in Q1 2025; platform still under development with no tokenized assets launched.
Issues $75M first tranche convertible debenture at 96% of par, 4% interest, 24-month maturity; conversion price tied to VWAP with 20% floor and 19.99% exchange cap.
BioSig closes share exchange with Streamex; new CEO and Chairman; pivots to RWA tokenization
BioSig completed acquisition of Streamex; Streamex shareholders receive 75% of fully diluted BSGM shares post-approval.
BioSig signs share exchange with Streamex; new CEO McPhie, Lekstrom as Chairman
Streamex shareholders initially get 19.9% of BioSig pre-transaction stock; after approval, 75% of fully diluted shares.
BioSig regains Nasdaq minimum bid price compliance after prior deficiency
Nasdaq notified BioSig on April 11, 2025 of bid price non-compliance.
Streamex stockholders receive 19.9% of BSGM common stock plus Series X convertible preferred, totaling 75% ownership on conversion.
BioSig Tech auditor Marcum resigns; CBIZ CPAs appointed; material weaknesses cited
Marcum LLP resigned as BioSig's auditor on April 30, 2025; CBIZ CPAs P.C. engaged same day.
BioSig issues 2.75M restricted shares to service providers for business development
Issued 2,750,000 restricted shares of common stock to certain service providers.
On April 11, 2025, Nasdaq notified BioSig that its common stock failed to maintain $1.00 minimum bid price for 30 consecutive business days.
BioSig regains full Nasdaq compliance; delisting risk resolved as of March 24
Nasdaq confirmed on March 24, 2025 that BioSig met the $2.5M stockholders' equity requirement for continued listing.
BioSig says it now meets Nasdaq equity rule after raising $4.85M in Jan-Mar 2025
Raised $4,847,497 from sale of 5,172,321 shares via ATM and private placement (Jan 17 – Mar 5, 2025).
BioSig raises $819K in private placement with warrants; ATM sales total $4M since mid-January
Sold 758,514 shares at $1.07974/share and 758,514 warrants exercisable at $0.95474/share for $818,998 aggregate.
BioSig enters $5M equity line with Lind Global; can sell shares at 95% of VWAP
Enters Equity Subscription Agreement with Lind Global Fund III for up to $5.0M of common stock over 36 months.
BioSig shareholders approve reverse stock split, increase share reserve by 3.5M
Reverse stock split approved at ratio range 1-for-2 to 1-for-10; Board to determine exact ratio and timing.
BioSig Technologies enters $8.5M ATM offering with H.C. Wainwright
Up to $8.5M of common stock may be sold at-the-market through H.C. Wainwright as agent.
BioSig Technologies wins dismissal of shareholder lawsuit seeking $288K damages
Court granted motion to dismiss on December 3, 2024.
BioSig regains Nasdaq minimum bid price compliance effective Nov 13, 2024
Nasdaq Staff notified BioSig on Nov 13, 2024 that it regained compliance with Listing Rule 5550(a)(2).
BioSig receives Nasdaq bid price deficiency; 180-day cure period granted
Nasdaq notified BioSig that bid price was below $1 from June 11 to Oct 23, 2024 failing continued listing requirement.
BioSig gets Nasdaq grace period until March 2025 for MVLS compliance; trading resumes Oct 23
Nasdaq granted grace period until March 7, 2025 to regain compliance with the MVLS Rule (market value of listed securities ≥ $35M).
Kenneth Londoner resigned as Chairman Feb 27 2024; Board appoints CEO Anthony Amato as Chairman effective Sept 11 2024.
BioSig delisted from Nasdaq, begins trading on OTCQB; appeal pending
Common stock commenced trading on OTCQB on July 23, 2024 after Nasdaq suspension on June 12, 2024.
Nasdaq delists BioSig Technologies; stock moves to OTC Pink, company appeals
Nasdaq Hearings Panel declined to reconsider delisting decision on June 24, 2024.
BioSig Technologies receives Nasdaq delisting notice; stock to trade on OTC Pink from June 12
Nasdaq Hearings Panel determined to delist BSGM for non-compliance with minimum stockholders' equity (Rule 5550(b)(2)).
BioSig Technologies appoints Ferdinand Groenewald as interim CFO after Hrkac resignation
Frederick Hrkac resigned as acting CFO and principal accounting officer effective June 5, 2024.
BioSig raises $3M via registered direct offering of 1.57M shares and warrants at $1.78
Issued 1,570,683 shares at $1.91 each in registered direct offering; gross proceeds ~$3M.
On April 28, 2026, the board of directors (the “Board”) of Streamex Corp. (the “Company”) appointed Mr. Mitchell Young Williams, the Company’s Chief Investment Officer, to serve as a non-independent director of the Board
Mr. McPhie and Mr. Lekstrom were appointed as new directors of the Board.
Morgan Lekstrom, co-founder and Chairman of Streamex, was appointed as the Chairman of the Board.
Mr. McPhie and Mr. Lekstrom were appointed as new directors of the Board.
Henry McPhie, co-founder and Chief Executive Officer of Streamex, was appointed the Company’s new Chief Executive Officer.
Anthony Amato, the Company’s Chief Executive Officer, President and Chairman of the Board of Directors of the Company (the “Board”), resigned as Chief Executive Officer, President and Chairman of the Board
Frederick D. Hrkac resigned from the Board
In connection with Mr. Amato’s resignation pursuant to the Share Purchase Agreement, the Company and Mr. Amato expect to enter into (i) a First Amendment to the Executive Employment Agreement (the “First Amendment”) and (ii) a letter agreement (the “Right to Place”).
On September 11, 2024, pursuant to Section 5.2 of the Company’s bylaws, the Board appointed the Company’s chief executive officer, Mr. Anthony Amato, as Chairman.
As previously announced on February 27, 2024, Kenneth L. Londoner, the former chairperson (“Chairman”) of the Board of Directors (the “Board”) of BioSig Technologies, Inc. (the “Company”) resigned from the Company.
On June 5, 2024, Mr. Frederick D. Hrkac resigned as acting chief financial officer and principal accounting officer of BioSig Technologies, Inc. (“BioSig” or “Company”) effective as of the same date.
Mr. Groenewald will serve as the Company’s interim chief financial officer, principal accounting officer and vice president of finance.
Max materiality 1.00 · Median 0.65 · Most common event other_material